13 results about "Neurotoxin" patented technology

Products, pharmaceutical compositions, methods of use, and kits are provided for treating a patient suffering from botulinum neurotoxin intoxication. Featured are single-domain variable heavy-chain (VHH) polypeptides (antibodies) that target and neutralize the light chain (LC) protease domains of botulinum neurotoxin (BoNT), i.e., BoNT LC / A and BoNT LC / B, and that advantageously provide late and post-exposure therapy for botulism patients. The LC / A toxin-binding and LC / B toxin-binding VHH polypeptides, which can be recombinantly produced, specifically bind to the LCs of the botulinum neurotoxins to inhibit toxin activity and treat intoxication.

This invention provides a method for producing Clostridium neurotoxins containing an exogenous activation loop, modified Clostridium neurotoxins, and pharmaceutical compositions. [Solution] A method for proteolytically processing a single-chain Clostridium neurotoxin into a corresponding double-chain Clostridium neurotoxin, comprising: providing a single-chain Clostridium neurotoxin; and contacting the single-chain Clostridium neurotoxin with enterokinase or factor Xa, wherein the single-chain Clostridium neurotoxin has the polypeptide sequence Cys-(Xaa) a -Ile-Asp / Glu-Gly-Arg-(Yaa) b - A method in which an activation loop containing Cys (SEQ ID NO: 1) is present, a=1 to 10, b=4 to 15, and enterokinase or factor Xa hydrolyzes the peptide bond of the activation loop, thereby producing a double-stranded Clostridium neurotoxin.

The present disclosure relates to methods of producing a 900 kDa BoNT / A complex, wherein the method does not comprise a step of precipitation during the purification process. Further provided herein are methods of preparing a Clostridium botulinum working cell bank (WCB).

Provided are a composition for stabilizing botulinum neurotoxin, a botulinum neurotoxin formulation including the same, and a polypeptide for use therein.

A botulinum neurotoxin serotype E (BoNT / E) for use in treating a disorder or a cosmetic condition, wherein the BoNT / E provides a maximum inhibition of neurotransmitter secretion from a target cell or tissue 13 days or less after administration to a human subject and the inhibition is reduced but is greater than 25% at day 14 following administration. A method for treating a disorder or a cosmetic condition, the method comprising administering the aforementioned BoNT / E.

A composition comprising a Clostridium botulinum neurotoxin serotype A (BoNT / A) complex comprising a plurality of variant species, wherein the variant species comprises BoNT / A with a C-terminal trunca

The present invention provides lateral flow assay devices and methods for detecting nicotinic acetylcholine receptor ligands in liquid samples. The device comprises a porous strip with multiple zones, including a sample deposition zone, a test visualization zone containing an immobilized nicotine conjugate, a control zone, and an absorbent zone. A recombinant acetylcholine receptor protein serves as a mobile agent, either pre-deposited on the strip or added to the sample. The recombinant protein comprises a ligand-binding domain of a nicotinic acetylcholine receptor conjugated to a visually-detectable reporter forming a receptor-reporter conjugate. When nicotinic acetylcholine receptor ligands are present in the sample, they competitively bind to the recombinant receptor protein, reducing binding to the immobilized nicotine conjugate and producing a visually detectable signal inversely proportional to ligand concentration. The invention provides rapid, simple, and field-deployable detection of receptor ligands in environmental samples, including cyanobacterial neurotoxins in surface waters, and biological samples for pharmacological and toxicological applications.

The present disclosure relates to methods for preparing Clostridium botulinum working cell bank. Further provided herein are methods of producing a composition comprising a 900 kDa BoNT / A complex, said method comprising an acid precipitation step.

The invention is directed to treatment of limb spasticity using a modified botulinum neurotoxin A (BoNT / A) comprising a BoNT / A light-chain and translocation domain, and a BoNT / B receptor binding domain (HC domain). Also provided are unit dosage forms of said modified BoNT / A and corresponding kits.

The present invention provides a method of treating a patient suffering from bladder pain syndrome, said method comprising administering a solution containing a clostridial neurotoxin into the bladder of the patient; increasing the volume of solution comprising the clostridial neurotoxin present within the bladder, thereby applying a mechanical force against the inner surface of the urothelial layer; and maintaining said volume of solution comprising the clostridial neurotoxin present within the bladder at a volume that does not give rise to patient micturition and for a duration of at least 30 minutes, thereby allowing the clostridial neurotoxin to diffuse across the urothelial layer and into the lamina propria, where the clostridial neurotoxin binds to primary sensory afferent nerve fibres, suppresses secretion of neurotransmitters therefrom, and alleviates bladder pain.

Disclosed herein are neurotoxin compositions and methods producing an increase in efficacy as well as an extended effect duration.

This document discloses clostridial neurotoxin (BoNT) or SNARE cleavage homolog variants, constructs, and methods of use thereof. The BoNT or SNARE cleavage homolog variants may include substitutions, deletions, or insertions of one or more amino acids or domains in the light chain.